Treating Acute Leukemias
in Europe
Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases
Overview
This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of patients with leukemia, join patient case-based discussions, and interact with experts.
Date and Location
October 16–17, 2024, Webinar
- 18.00 – 21.00 (UTC+1) Central European Time
Co-Chairs
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, United Kingdom
Nicola Gökbuget, MD
University Hospital Frankfurt, Germany
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Spain
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within Europe. Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML prognosis and management, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges in Europe. Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment. |
Day 1: Wednesday, October 16, 2024
| Time (UTC +1) | Topic | Presenter |
| 18.00 – 18.10 | Welcome and meeting overview | Elias Jabbour |
| 18.10 – 18.25 | Latest achievements and developments in ALL and AML | Elias Jabbour |
| 18.25 – 18.40 | Review of prognostic value of MRD in ALL and AML | Josep-Maria Ribera |
| 18.40 – 18.50 | Best practices for first-line treatment in ALL | Elias Jabbour |
| 18.50 – 19.05 | AYA patients with ALL: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients | Nicola Gökbuget |
| 19.05 – 19.35 |
ALL case-based panel discussion
|
Elias Jabbour and case presenters |
| 19.35 – 19.45 | Break | |
| 19.45 – 20.10 | Genetic characterization and risk stratification of AML; role of FLT3 and IDH in AML and special considerations for young and fit patients | Naval Daver |
| 20.10 – 20.25 | Therapeutic approaches in high-risk and frail patients with AML | Charles Craddock |
| 20.25 – 20.50 | Panel discussion: Open questions in ALL and AML – regional challenges (transplant, CAR T, studies, and other) | Elias Jabbour and all faculty |
| 20.50 – 21.00 | Session close | Elias Jabbour |
Day 2: Thursday, October 17, 2024
| Time (UTC +1) | Topic | Presenter |
| 18.00 – 18.10 | Welcome to Day 2 | Naval Daver |
| 18.10 – 18.30 | Current treatment options for relapsed ALL in adult and elderly patients | Elias Jabbour |
| 18.30 – 18.50 | Long-term safety considerations for leukemias (focus on ALL) | Nicola Gökbuget |
| 18.50 – 19.10 | Current and future role of transplantation in acute leukemias in Europe | Josep-Maria Ribera |
| 19.10 – 19.20 | Break | |
| 19.20 – 19.40 | Current treatment options for relapsed AML in adult and elderly patients | Charles Craddock |
| 19.40 – 20.10 |
AML case-based panel discussion
|
Naval Daver and case presenters |
| 20.10 – 20.50 |
Panel discussion: How treatment in first line influences further therapy approaches in ALL and AML
|
Naval Daver and all faculty |
| 20.50 – 21.00 | Session close | Naval Daver |
